{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-26-001482","form_type":"8-K","ticker":"VANI","cik":"0001266806","company_name":"Vivani Medical, Inc.","filed_at":"2026-08-13T20:31:12+00:00","discovered_at":"2026-08-13T20:33:00.341809+00:00","generated_at":"2026-08-13T20:34:09.321696+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vivani Q2 net loss $6.4M; SLIM-1 fully enrolled; Novo Nordisk deal; Cortigent merger on track","bullets":["Q2 2026 net loss $6.4M vs $7.1M in Q2 2025; cash $20.8M at June 30, 2026.","SLIM-1 Phase 1 trial of NPM-139 fully enrolled (20 participants); top-line data expected November 2026.","Non-exclusive agreement with Novo Nordisk to evaluate NPM-139 semaglutide implant; no exclusivity provisions.","Cortigent merger with ClearOne expected to close Q3 2026; post-merger company to trade as CRGT on Nasdaq.","August J. Moretti appointed to board; former CFO of 4D Molecular Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-26-001482","json":"https://secwatch.observer/filing/0001753926-26-001482.json","markdown":"https://secwatch.observer/filing/0001753926-26-001482.md","text":"https://secwatch.observer/filing/0001753926-26-001482.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626001482/0001753926-26-001482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1266806/000175392626001482/vani-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T20:34:09.321696+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}